$60,000 of CVS HEALTH lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to pharmaceutical supply chains. Issues related to Medicare Part D, Medicare Advantage and Medicaid. Issues related to employer, small group, and individual insurance markets."
You can find more data on corporate lobbying on Quiver Quantitative.
CVS Congressional Stock Trading
Members of Congress have traded $CVS stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $CVS stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 02/25.
- REPRESENTATIVE J. FRENCH HILL sold up to $50,000 on 01/31.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 01/24.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 01/15.
- REPRESENTATIVE THOMAS R. SUOZZI sold up to $15,000 on 10/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
CVS Insider Trading Activity
CVS insiders have traded $CVS stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CVS stock by insiders over the last 6 months:
- MICHAEL F MAHONEY purchased 30,000 shares for an estimated $2,001,000
- JAMES DAVID CLARK (SVP, Cont & Chief Acct Officer) sold 7,513 shares for an estimated $498,487
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CVS Hedge Fund Activity
We have seen 511 institutional investors add shares of CVS stock to their portfolio, and 1,223 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 12,819,148 shares (+26.6%) to their portfolio in Q4 2024, for an estimated $575,451,553
- DAVIS SELECTED ADVISERS added 11,018,438 shares (+2998.1%) to their portfolio in Q4 2024, for an estimated $494,617,681
- DODGE & COX added 7,075,209 shares (+11.2%) to their portfolio in Q4 2024, for an estimated $317,606,132
- PZENA INVESTMENT MANAGEMENT LLC added 6,475,271 shares (+49.3%) to their portfolio in Q4 2024, for an estimated $290,674,915
- MORGAN STANLEY removed 4,690,278 shares (-21.1%) from their portfolio in Q4 2024, for an estimated $210,546,579
- BANK OF AMERICA CORP /DE/ removed 4,423,903 shares (-33.2%) from their portfolio in Q4 2024, for an estimated $198,589,005
- GOLDMAN SACHS GROUP INC removed 4,362,778 shares (-45.0%) from their portfolio in Q4 2024, for an estimated $195,845,104
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CVS Analyst Ratings
Wall Street analysts have issued reports on $CVS in the last several months. We have seen 4 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Edward Jones issued a "Buy" rating on 01/30/2025
- Cowen & Co. issued a "Buy" rating on 12/20/2024
- Wells Fargo issued a "Overweight" rating on 11/18/2024
- RBC Capital issued a "Underperform" rating on 10/23/2024
- Piper Sandler issued a "Overweight" rating on 10/21/2024
To track analyst ratings and price targets for CVS, check out Quiver Quantitative's $CVS forecast page.
CVS Price Targets
Multiple analysts have issued price targets for $CVS recently. We have seen 5 analysts offer price targets for $CVS in the last 6 months, with a median target of $66.0.
Here are some recent targets:
- George Hill from Deutsche Bank set a target price of $66.0 on 12/03/2024
- Stephen Baxter from Wells Fargo set a target price of $66.0 on 11/18/2024
- Ann Hynes from Mizuho Securities set a target price of $66.0 on 10/24/2024
- David MacDonald from Truist Financial set a target price of $76.0 on 10/21/2024
- Jessica Tassan from Piper Sandler set a target price of $72.0 on 10/21/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
